Cooperative Drug Development Group (Cddg) for the Treatment of Serious Mental Illness

The summary for the Cooperative Drug Development Group (Cddg) for the Treatment of Serious Mental Illness grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Cooperative Drug Development Group (Cddg) for the Treatment of Serious Mental Illness: The intent of this solicitation is to invite applications from academic and pharmaceutical/biotechnology industry investigators interested in participating with the National Institute of Mental Health (NIMH) in a Cooperative Drug Development Group (CDDG) program. The goal of the CDDG is to support proof-of- concept studies of novel mechanism drug candidates and promising investigational new drugs (IND) for the treatment of serious mental disorders. The CDDG will specifically focus on testing drugs directed at novel targets for mood disorders, schizophrenia, eating disorders, obsessive-compulsive disorder, fragile x, autism, and other serious mental disorders. The CDDG will support studies to rapidly assess safety and tolerability in normal human subjects and preliminary efficacy studies in the target patient population. The proof-of-concept, early phase II or other studies such as clinical dose optimization, pharmacokinetics, and pharmacodynamics studies, should determine with reasonable certainty whether or not a drug candidate is sufficiently safe and effective to warrant further clinical and commercial development. These data will be essential for fostering partnerships between academic investigators and the private sector (small businesses, pharmaceutical, and biotechnology companies) to further test the drug candidate in future larger-scale, longer-term studies in the target population. The goal of the CDDG is to foster these long-term partnerships between NIMH, academia, and industry that will advance the development and testing of fundamentally new, rationally designed medications and treatments for serious mental disorders. Academic and/or pharmaceutical industry components of each CDDG should contribute unique scientific expertise towards the common goal of translating basic science findings into innovative pharmacological treatments for serious mental disorders. Each partnership or group must consist of a multi-disciplinary team of scientists with appropriate expertise to address the development and evaluation of novel IND- ready compounds for testing in humans. Scientists from both academia and pharmaceutical industry are encouraged to participate within a CDDG. Scientists from foreign institutions and NIH Intramural laboratories may participate in some aspects, as noted in other sections of this application. The CDDG is most appropriate for applications that include collaborations, Research Projects or core components from academia and the private sector (e.g., pharmaceutical, chemical, or biotechnological companies). It is anticipated that the interaction of academic and non-profit research institutions with industry and NIMH via the CDDG model will: 1) accelerate the development of new therapeutics for mood disorders, schizophrenia, eating disorders, obsessive-compulsive disorder, fragile x, autism, and other serious mental disorders; 2) increase the availability of new IND-ready compounds suitable for testing in humans; and 3) facilitate the development and validation of new clinical measures or biomarkers suitable for use in human proof-of-concept trials of novel therapeutics for mood disorders, schizophrenia, eating disorders, obsessive-compulsive disorder, fragile x, autism, and other serious mental disorders. Small businesses without academic and/or industry partners are encouraged to respond to related Program Announcements: Pharmacologic Agents and Drugs for Mental Disorders (SBIR Award) [http://grants.nih.gov/grants/guide/pa-files/PA-02- 027.html] and Development of PET and SPECT Ligands for Brain Imaging (SBIR Award) [http://grants.nih.gov/grants/guide/pa-files/PA-02-028.html].
Federal Grant Title: Cooperative Drug Development Group (Cddg) for the Treatment of Serious Mental Illness
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-MH-05-003
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.242
CFDA Descriptions: Mental Health Research Grants
Current Application Deadline: No deadline provided
Original Application Deadline: Aug 25, 2004
Posted Date: May 10, 2004
Creation Date: May 10, 2004
Archive Date: Oct 14, 2004
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster FBOWebmaster@OD.NIH.GOV NIH OER Webmaster
Similar Government Grants
Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (U01 Clinical ...
Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (Collaborative...
Innovative Epidemiologic Approaches for Understanding Long-term Health Outcomes of HIV-exp...
Advancing Sustained/Extended Release for HIV Prevention (A-SER) (R01 Clinical Trial Not Al...
Explainable Artificial Intelligence for Decoding and Modulating Neural Circuit Activity Li...
Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...
Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...
Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health
Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines (U01 Clinica...
Understanding Phage Biology to Support the Development of Bacteriophage Therapy (R21 Clini...
Strategies to Improve Health Outcomes and to Reduce Disparities in Rural Populations (R01 ...
Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical T...
Organotypic Culture Models developed from Experimental Animals for Chemical Toxicity Scree...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com